Natco Pharma launches Valsartan-Sacubitril in India

Hyderabad-based Natco Pharma has launched Valsartan-Sacubitril tablet under its brand VALSAC, the company informed the bourses. This tablet is used for certain types of heart failure and keeps blood vessels from narrowing.

The company has launched VALSAC in 50 mg and 100 mg strengths at an MRP of Rs. 45.0 and Rs. 55.0, per tablet, respectively.

Recently, the company has diversified its portfolio by entering into agrichemicals with an investment of Rs. 100 crore. During the recent quarter Q2FY19, the company’s revenue mix comprises of Formulations (75 per cent) and API (11 per cent). Also, the revenue and net profit also spiked by 35 per cent and 115 per cent respectively on YoY basis.

Natco Pharma is involved in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).

On Monday, the stock opened at Rs. 677.90 per share and made an intraday low of Rs. 665 on the BSE. At 14:29 hours, the stock was trading nearly at Rs. 667.00, down 1.70 per cent on the BSE. The company had hit its 52-week high of Rs. 1,004.40 on January 29, 2018 and its 52-week low of Rs. 637.40 on October 9, 2018 on the BSE.